Latest News

Kalbe Educates on The Prevention of Cervical Cancer

Be Aware, Smart, and Protected from Cervical Cancer

Kalbe Educates on The Prevention of Cervical Cancer

Press Release No.  004/KFCP-DIR/PR/I/14

Jakarta, 25 January 2014 - PT Kalbe Farma Tbk (Kalbe) through its subsidiary KalGen DNA Laboratory and collaborating with SaveHer Community is holding a discussion on the prevention of cervical cancer with the theme Be Aware, Smart, and Protected from Cervical Cancer.  The event is held in conjunction with the Cervical Cancer Awareness Month at Kalcare Lotte Shopping Avenue outlet, Ciputra World, on Saturday, 25 January 2014, presenting experts Dr. dr. Junita Indarti, SpOG(K), (Chairperson of Women Health Center, RSCM and caretaker of the Association of Cervical Pathology and Colposcopy Indonesia).

”This event will present the awareness and prepare active women on the importance of the prevention of cervical cancer for herself or her friends," said dr. Virgi Saputra, Marketing Manager of KALGen DNA, ”Many women are unaware of the prevention measures of cervical cancer because they believe that they are not at risk. Whereas in reality, this deadly disease showed no symptoms at all in the early stages.” he said.

Cervical cancer is a cancer that affected the cervix area and could spread to other organs in the human body.  Cervical cancer is caused by the HPV virus (Human Papilloma Virus). The deadly cervical cancer showed no symptoms in its early stages. Furthermore, HPV infection (Human Papilloma Virus) is a common infection that affects 50-80% of women who are sexually active. A woman can contract or transfer the HPV virus without realizing it.

At the moment, there are numerous methods on early detection of cervical cancer that needs to be known by women, such as cytology and HPV detection.  Cytology examination (cyte: cellular, logy: science) aims to detect the changes in the cervical cells that are caused by inflammation or cell mutation toward malignancy. Cytology examination is divided in two segments, the conventional Pap smear, and LBC (Liquid-based Cytology). HPV Examination intends to detect HPV infection even before the changes of cervical cells. The examination material is taken from the same specimen with liquid-based cytology. HPV infection check has high sensitivity on detection precancerous lesions.

The National Comprehensive Cancer Network and American College of Obstetricians & Gynecologists advises on simultaneous cytology and HPV (co-testing) on women 30 years or older.  The combined examination of LBC and HPV gives maximum accuracy of 100% sensitivity and has the negative prediction value (NPV) of 100%. This means a negative result would give the patient a peace of mind, given the possibilities of contracting cervical cancer in the next 3-5 years is only 1:1,000, and it is also more cost-effective since she would only require another check up in the next 3 years.  

KalGen DNA at a glance

KalGen DNA is a part of PT Bifarma Adiluhung, a subsidiary of Kalbe Farma, and is a Joint venture company between Kalbe Genomics with DNA Laboratories Sdn Bhd (DNA LAB) Malaysia that was established in 2012. KalGen DNA has the tagline of “Detect Early Save Life” and provide the best services with professional molecular analysis, high-quality materials, diagnostic equipment, process and internal process, and is also internationally validated by the WHO's HPV Lab Net Proficiency Study.

KalGen DNA provides the HPV DNA Genotyping services to detect cervical cancer earlier with higher sensitivity. The examinations done at KalGen Lab at the moment are screening and early detection of cervical cancer with HPV genotyping and Liquid-based Cytology. These two tests provide a 99.9% sensitivity, that when the second test is found negative, one is pronounced safe from cervical cancer up to the next 3 years. This gives a beneficial solution for the patient when compared to the conventional Pap smear that only gives 56% of sensitivity and requires annual exam.

Kalbe at a glance
PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio; prescription medicines (Cefspan, Brainact, Broadced, etc); health products division that handles over-the-counter medications (Woods, Promag, Mixagrip, Komix, Fatigon, etc) and ready-to-drink energy drinks (Hydro Coco, Extra Joss, Nitros), nutrition division (ChilKid, Prenagen, Diabetasol, etc); and distribution division. Kalbe currently has more than 20 subsidiaries, 11 production facilities with international standard, and employs more than 15,000 employees and 4,000 sales force and marketing agents, dispersed across more than 65 branches throughout Indonesia. From 1991, Kalbe is listed at Indonesia Stock Exchange (IDX:KLBF).

Print
4952 Rate this article:
3.7

Please login or register to post comments.

Name:
Email:
Subject:
Message:
x